Marli E. Ebus

Utrecht, UT 3584CS, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Exploring high-throughput drug sensitivity testing in neuroblastoma cell lines and patient-derived tumor organoids in the era of precision medicine.

Exploring high-throughput drug sensitivity testing in neuroblastoma cell lines and patient-derived tumor organoids in the era of precision medicine.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 15, 2023

MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma.

MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma.

Journal: Frontiers in oncology

Published: December 22, 2022

A Common Genomic Denominator for Neuroblastoma and Differentiated Thyroid Carcinoma? A Case Series in Children.

A Common Genomic Denominator for Neuroblastoma and Differentiated Thyroid Carcinoma? A Case Series in Children.

Journal: Clinical oncology (Royal College of Radiologists (Great Britain))

Published: March 07, 2022

Defects in 8-oxo-guanine repair pathway cause high frequency of C > A substitutions in neuroblastoma.

Defects in 8-oxo-guanine repair pathway cause high frequency of C > A substitutions in neuroblastoma.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: July 22, 2021

Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma.

Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma.

Journal: The Journal of clinical investigation

Published: October 08, 2019

RAS-MAPK Pathway-Driven Tumor Progression Is Associated with Loss of CIC and Other Genomic Aberrations in Neuroblastoma.

RAS-MAPK Pathway-Driven Tumor Progression Is Associated with Loss of CIC and Other Genomic Aberrations in Neuroblastoma.

Journal: Cancer research

Published: April 11, 2018

Neuroblastoma is composed of two super-enhancer-associated differentiation states.

Neuroblastoma is composed of two super-enhancer-associated differentiation states.

Journal: Nature genetics

Published: December 19, 2016

Enhancer of zeste homologue 2 plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activity.

Enhancer of zeste homologue 2 plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activity.

Journal: European journal of cancer (Oxford, England : 1990)

Published: September 13, 2016

Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma.

Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: February 08, 2015

Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations.

Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations.

Journal: Nature genetics

Published: January 15, 2015

Newly-derived neuroblastoma cell lines propagated in serum-free media recapitulate the genotype and phenotype of primary neuroblastoma tumours.

Newly-derived neuroblastoma cell lines propagated in serum-free media recapitulate the genotype and phenotype of primary neuroblastoma tumours.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 22, 2013

LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression.

LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression.

Journal: Nature genetics

Published: March 27, 2012

Showing 1-12 of 14

Last Updated: 09/26/2026